A trial fibrillation (AF) is the most commonly encountered arrhythmia worldwide, with an estimated prevalence of ≈3% in adults ≥20 years of age 1 and with an even greater prevalence in subjects with conditions such as hypertension, valvular heart disease, or chronic kidney disease. AF is classified according to its pattern of occurrence, and recent guidelines have proposed a consensus definition of the temporal occurrence of AF. Paroxysmal AF is self-terminating and lasts no longer than 7 days; AF episodes lasting longer than 7 days or necessitating termination by cardioversion are defined as persistent AF; and permanent AF is defined as AF without intercurring sinus rhythm, which is accepted by the patient and the physician. 
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An often debated issue is whether the type and the duration of AF affect stroke risk. Early findings from the SPAF trials (Stroke Prevention in Atrial Fibrillation) 2 and an analysis of the ACTIVE W study (Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events) 3 suggested a similar stroke risk in all types of AF. However, these studies were limited by methodological issues such as moderate sample sizes with relatively low event rates. More recently, subanalyses from the large phase III trials of non-vitamin K oral anticoagulants (NOAC) yielded lower incidences of stroke and systemic embolism in patients with paroxysmal as compared with persistent or permanent AF. [4] [5] [6] [7] In this issue of the journal, similar data are presented from the large ENGAGE AF-TIMI 48 trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48), which compared the effects of the NOAC edoxaban to warfarin in patients with AF and stroke risk factors. 8 This trial is the largest of all NOAC trials comprising 21 105 patients, has the longest follow-up period, and provides data on >650 primary outcome events of stroke and systemic embolism. The present well-conducted substudy provides information on 3 important issues: (1) After adjusting for important baseline confounders, paroxysmal AF was associated with a lower stroke risk of 1.49% per year compared with persistent AF (1.83% per year; P=0.015) and permanent AF (1.95% per year; P=0.004). Of note, these numbers were observed in subjects who were all undergoing oral anticoagulation therapy. (2) All-cause mortality was also lower in paroxysmal than in persistent or permanent AF, probably foremost reflecting the fact that patients with permanent AF have more advanced heart disease and more comorbidities.
6,7 (3) There was no effect modification by AF pattern on the efficacy and the safety of edoxaban.
These observations are in line with those made in other NOAC trials. [4] [5] [6] [7] Although the risk for stroke or systemic embolism is lower in patients with paroxysmal AF as compared with patients with persistent/permanent AF; it still warrants anticoagulation therapy. This need is underpinned if one considers stroke incidences according to AF pattern in patients who are not undergoing oral anticoagulation. There is one retrospective, yet comprehensive study that assessed stroke risk in 6563 patients enrolled in the ACTIVE A and in the AVERROES (Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment) trials. 9 By study protocol, all of these patients were not receiving anticoagulation but were only treated with aspirin. 9 Yearly ischemic stroke rates were 2.1%, 3.0%, and 4.2% for subjects with paroxysmal, persistent, or permanent AF, substantially higher than those observed in the NOAC trials including ENGAGE AF-TIMI 48 9 . In this large population of nonanticoagulated patients, AF pattern turned out to be a strong independent predictor of stroke risk. All aforementioned analyses of the recent NOAC trials emphasize the fact that the effects of these new anticoagulants compared with warfarin are preserved in all AF patterns. [4] [5] [6] [7] Particularly, the safety profile of these compounds (ie, generally lower bleeding risks compared with vitamin K antagonists) allows the treating physician to protect patients with all types of AF from thromboembolic complications.
One important remaining research question at present is whether the above-described observations apply also to patients with subclinical AF. 10, 11 Recent studies in patients with permanent pacemakers or implantable cardioverter defibrillators have demonstrated an increased stroke risk even in patients with short-lasting episodes of subclinical AF. 
